Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 12,962,959Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Gran

02 9Neupogen

PharmaCompass

01

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2020 Revenue in Millions : 225

2019 Revenue in Millions : 264

Growth (%) : -15

blank

02

Brand Name : Gran

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gran

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2020 Revenue in Millions : 58

2019 Revenue in Millions : 61

Growth (%) : -5

blank

03

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2021 Revenue in Millions : 168

2020 Revenue in Millions : 225

Growth (%) : -25

blank

04

Brand Name : Gran

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gran

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2021 Revenue in Millions : 53

2020 Revenue in Millions : 58

Growth (%) : 3

blank

05

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 144

2021 Revenue in Millions : 168

Growth (%) : -14

blank

06

Brand Name : Gran

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gran

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 62

2021 Revenue in Millions : 53

Growth (%) : 17

blank

07

Brand Name : Gran

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gran

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Hematology

Currency : USD

2023 Revenue in Millions : 47

2022 Revenue in Millions : 62

Growth (%) : -16

blank

08

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Blood Related Disorders

Currency : USD

2015 Revenue in Millions : 1,159

2014 Revenue in Millions : 1,049

Growth (%) : -9%

blank

09

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Blood Disorders

Currency : USD

2017 Revenue in Millions : 549

2016 Revenue in Millions : 765

Growth (%) : -28

blank

10

Brand Name : Neupogen

Filgrastim

arrow
Antibody Engineering
Not Confirmed

Brand Name : Neupogen

arrow
Antibody Engineering
Not Confirmed

Filgrastim

Main Therapeutic Indication : Blood Disorders

Currency : USD

2018 Revenue in Millions : 365

2017 Revenue in Millions : 549

Growth (%) : -34%

blank